ALK beats analyst expectations on all parameters

Allergy firm ALK is continuing to gain momentum, ending Q1 2022 on a good note after a positive 2021. The company has grown both in terms of operations and on the bottom line.

Photo: ALK / PR

The first three months of the year are behind us, and as allergy season looms for hay fever sufferers, ALK has released its Q1 report.

The report shows significant sales growth for both SLIT tablets and SCIT/SLIT eye drops, with both product groups beating analysts’ sales expectations.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs